Kyprolis

J&J and Sanofi's multiple myeloma tit-for-tat continues, as subcutaneous Darzalex wins combo approval
J&J and Sanofi's multiple myeloma tit-for-tat continues, as subcutaneous Darzalex wins combo approval
Endpoints
JNJ
Sanofi
Multiple Myeloma
Sarclisa
Kyprolis
Darzalex
Flag link:
Sanofi keeps nipping at J&J's heels as Sarclisa notches new FDA approval in multiple myeloma
Sanofi keeps nipping at J&J's heels as Sarclisa notches new FDA approval in multiple myeloma
Endpoints
Sanofi
JNJ
Sarclisa
Kyprolis
Multiple Myeloma
Flag link:
ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama
ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama
Pharmaforum
ASCO 2020
Amgen
AstraZeneca
Bristol-Myers Squibb
cancer
CAR-T
COVID-19
Keytruda
Kyprolis
Tagrisso
Flag link:
Sanofi takes aim at J&J's myeloma star Darzalex with latest Sarclisa trial win
Sanofi takes aim at J&J's myeloma star Darzalex with latest Sarclisa trial win
Fierce Pharma
Sanofi
Sarclisa
Multiple Myeloma
Amgen
Kyprolis
Flag link:
Amgen's Kyprolis, J&J's Darzalex team up on myeloma survival win
Amgen's Kyprolis, J&J's Darzalex team up on myeloma survival win
Fierce Pharma
Amgen
Kyprolis
JNJ
Darzalex
Multiple Myeloma
Flag link:
Can Amgen's new-and-improved Kyprolis kick-start myeloma sales?
Can Amgen's new-and-improved Kyprolis kick-start myeloma sales?
Fierce Pharma
Amgen
Kyprolis
Multiple Myeloma
Flag link:
Amgen focuses on migraine launch as growth remains slow
Amgen focuses on migraine launch as growth remains slow
Biopharma Dive
Amgen
earnings
Repatha
Kyprolis
Prolia
Xgeva
Flag link:
Amgen kicks off 2018 with double the good news for slow-growing Kyprolis
Amgen kicks off 2018 with double the good news for slow-growing Kyprolis
Fierce Pharma
Amgen
Kyprolis
Multiple Myeloma
Flag link:
Amgen's Kyprolis improves overall survival in blood cancer patients
Amgen's Kyprolis improves overall survival in blood cancer patients
Reuters
Amgen
Kyprolis
Multiple Myeloma
Flag link:
What Kyprolis Could Do for Amgen’s Revenue Growth
What Kyprolis Could Do for Amgen’s Revenue Growth
Market Realist
Kyprolis
Amgen
Multiple Myeloma
Flag link:
Amgen's battered Kyprolis nabs a survival win, slashing death risk in Revlimid-chemo combo
Amgen's battered Kyprolis nabs a survival win, slashing death risk in Revlimid-chemo combo
Fierce Pharma
Amgen
Kyprolis
Revlimid
Celgene
Takeda
Velcade
Multiple Myeloma
Flag link:
Longer survival seen with Amgen's Kyprolis vs Velcade in myeloma study
Longer survival seen with Amgen's Kyprolis vs Velcade in myeloma study
Yahoo/Reuters
Amgen
Kyprolis
Velcade
Takeda
Multiple Myeloma
Flag link:
Amgen’s Backup Plan for Kyprolis (AMGN)
Amgen’s Backup Plan for Kyprolis (AMGN)
Investopedia
Amgen
Kyprolis
Multiple Myeloma
Flag link:
Amgen's Kyprolis Fails To Met Endpoint, But It's Not All Bad News
Amgen's Kyprolis Fails To Met Endpoint, But It's Not All Bad News
Yahoo/Benzinga
Amgen
Kyprolis
clinical trials
Multiple Myeloma
Flag link:
Amgen's multiple myeloma drug falls short in late stage study
Amgen's multiple myeloma drug falls short in late stage study
Yahoo/Reuters
Amgen
Multiple Myeloma
Kyprolis
clinical trials
Takeda
Velcade
Flag link:
Amgen Gets CHMP's Positive Opinion To Extend Indication Of Kyprolis For Relapsed Multiple Myeloma Treatment
Amgen Gets CHMP's Positive Opinion To Extend Indication Of Kyprolis For Relapsed Multiple Myeloma Treatment
Yahoo/Benzinga
Amgen
CHMP
Kyprolis
Multiple Myeloma
Flag link:
Drug makers fuming at ‘overpriced’ values placed on their myeloma drugs
Drug makers fuming at ‘overpriced’ values placed on their myeloma drugs
Stat
Multiple Myeloma
Amgen
Kyprolis
Flag link:
Amgen's Kyprolis stands its ground against new J&J, BMS rivals
Amgen's Kyprolis stands its ground against new J&J, BMS rivals
Fierce Pharma
Amgen
Kyprolis
JNJ
Bristol-Myers Squibb
Multiple Myeloma
Darzalex
Empliciti
AbbVie
Takeda
Ninlaro
Flag link:
New myeloma meds work better than the old, but they're far too expensive: Report
New myeloma meds work better than the old, but they're far too expensive: Report
Fierce Biotech
Multiple Myeloma
Bristol-Myers Squibb
Amgen
Takeda
Empliciti
Kyprolis
Ninlaro
Celgene
Revlimid
Flag link:
Amgen balks over meeting to review cost of bone cancer drugs
Amgen balks over meeting to review cost of bone cancer drugs
Stat
Amgen
drug pricing
Kyprolis
Multiple Myeloma
Flag link:

Pages